JAK1 and vitiligo: The patient was prescribed Opzelura (ruxolitinib) 1.5% topical cream, an inhibitor of the JAK1 and JAK2 proteins prevalent in the immune reaction responsible for vitiligo [20], as well as tacrolimus 0.1% topical ointment, another immunosuppressant, and was instructed to apply them over the affected area.